[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 declaring a proposed sale of 400 founder shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,572.00. The filing lists 2,046,854 shares outstanding and an approximate sale date of 08/28/2025 on NASDAQ. The shares were acquired as founders shares on 05/17/2022 from the issuer and payment was recorded on the same date. The filing also discloses recent 10b5-1 sales by the same person: 1,600 shares sold on 08/27/2025 for gross proceeds of $22,392.00. The filer affirms compliance statements required under Rule 144 and 10b5-1.

Positive

• Transparent disclosure of proposed sale details including broker, amount, and sale date
• Compliance with Rule 144 and 10b5-1 documented, including acquisition origin and attestation
• Relatively small size of the proposed sale versus shares outstanding, limiting immediate market impact

Negative

• Insider selling is disclosed, which some investors may view negatively despite small size

Insights

Securities Analyst

TL;DR: Insider sale disclosed; volume is small relative to outstanding shares and appears procedural.

The Form 144 reports a proposed sale of 400 founder shares with a stated market value of $5,572 and prior 10b5-1 sales of 1,600 shares yielding $22,392. Against 2,046,854 shares outstanding, the disclosed transactions represent a very small percentage of the float, suggesting limited immediate dilution or market impact. The use of a broker and the 10b5-1 disclosure indicate the seller is following established compliance protocols.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144/10b5-1 requirements; shows procedural transparency.

The filing includes acquisition details (founders shares dated 05/17/2022) and a representation that no undisclosed material adverse information is known. That signature-level attestation and the explicit listing of broker, sale dates, and amounts meet formal disclosure expectations. No indications of unusual or large-scale insider liquidation are present in the filing itself.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	400	5572.00	2046854	08/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			400	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for CVKD report for sale?

The filing reports a proposed sale of 400 founder common shares with an aggregate market value of $5,572.00.

When is the approximate sale date listed on the Form 144?

The approximate date of sale is listed as 08/28/2025.

Who is the broker handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, New York, NY).

What recent insider sales does the filing disclose?

The filing discloses 10b5-1 sales of 1,600 shares on 08/27/2025 for gross proceeds of $22,392.00.

How many shares outstanding does the filing list?

The filing lists 2,046,854 shares outstanding.